{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/acne-vulgaris/background-information/definition/","result":{"pageContext":{"chapter":{"id":"13ced928-40f6-593c-8ae8-3d619c885e2e","slug":"definition","fullItemName":"Definition","depth":2,"htmlHeader":"<!-- begin field 74220b19-bad0-4a15-b85f-974082258aff --><h2>What is it?</h2><!-- end field 74220b19-bad0-4a15-b85f-974082258aff -->","summary":"","htmlStringContent":"<!-- begin item a59905ce-b759-4815-931e-41daa0fa18e2 --><!-- begin field 8dc36ac7-5473-4a59-8876-f487cbeecd49 --><p><strong>Acne vulgaris is a chronic inflammatory skin condition affecting mainly the face (99% of cases), back (60% of cases) and chest (15% of cases).</strong></p><ul><li>Acne is characterised by blockage and inflammation of the pilosebaceous unit (the hair follicle, hair shaft and sebaceous gland). It presents with lesions which can be non-inflammatory, inflammatory or a mixture of both.</li><li>Non-inflamed lesions are known as comedones which may be open (blackheads), closed (whiteheads) or microcomedones (clinically invisible).</li><li>Inflammatory acne lesions include papules and pustules (5 mm or less in diameter) — in more severe disease these can develop into larger deeper pustules and nodules.</li><li>Most people with acne have a mixture of inflammatory and non-inflammatory lesions.</li><li>There is no universally agreed grading system for acne but it is often categorised by lesion type and severity into:<ul><li><strong>Mild acne</strong> — predominantly non-inflamed lesions (open and closed comedones) with few inflammatory lesions.</li><li><strong>Moderate acne</strong> — more widespread with an increased number of inflammatory papules and pustules.</li><li><strong>Severe acne</strong> — widespread inflammatory papules, pustules and nodules or cysts. Scarring may be present.</li></ul></li><li>Conglobate acne is a rare and severe form of acne found most often in men – it presents with extensive inflammatory papules, suppurative nodules (which may coalesce to form sinuses) and cysts on the trunk and upper limbs.</li><li>Acne fulminans is a sudden severe inflammatory reaction that precipitates deep ulcerations and erosions, sometimes with systemic effects (such as fever and arthralgia).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Dawson, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Moradi Tuchayi, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Asai, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Gollnick, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Nast, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">Zaenglein, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/acne-vulgaris/references/\">BMJ Best Practice, 2017</a>]</p><!-- end field 8dc36ac7-5473-4a59-8876-f487cbeecd49 --><!-- end item a59905ce-b759-4815-931e-41daa0fa18e2 -->","topic":{"id":"4f10413c-64a7-5bb3-9003-1093b58e5700","topicId":"7737f6eb-1907-461e-a10b-166056e652b7","topicName":"Acne vulgaris","slug":"acne-vulgaris","lastRevised":"Last revised in August 2020","chapters":[{"id":"c13b5a16-bcf3-5b36-8dce-af226250264d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"318cce93-72af-5473-9c96-2577e69df14c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6aac7922-c920-5394-bc2c-08ae3e93e4c5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b6ea59d7-e11c-59ba-ae3a-d12eda1c224b","slug":"changes","fullItemName":"Changes"},{"id":"501eff80-f5ab-5966-b79a-791cec9fcf7c","slug":"update","fullItemName":"Update"}]},{"id":"017f5393-8a9f-5cdb-9799-d9c32c6b50e9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"32769738-e7d1-5c7a-a6ac-7e242b6ad659","slug":"goals","fullItemName":"Goals"},{"id":"60cde7a9-d789-5629-a7d6-e14882c6caf9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f91e328f-4d37-5a01-ab6d-edf7165acdaf","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"01961474-a4a0-5330-bc03-aca2c93fd7ed","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"867bb680-22ea-5d29-88b0-f219f9e8dae8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8447443c-c6e1-5af4-ab33-68aa460c97b0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"10279ff1-6a1f-5af9-97b1-73405139911f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"13ced928-40f6-593c-8ae8-3d619c885e2e","slug":"definition","fullItemName":"Definition"},{"id":"290d67e9-4d5f-5a03-bafc-46380a14e964","slug":"causes","fullItemName":"Causes"},{"id":"2c90cfb7-ff4f-535b-b067-7b291de8de21","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5665dddd-4418-59f5-8480-8d73bc88b392","slug":"complications","fullItemName":"Complications"},{"id":"8e63da8e-8783-584a-962f-77fc8f5cda7c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"cac20ff4-4d28-5a3d-ab66-5ad66ea6485d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"318b12a5-f38e-5aa0-866d-258e0bc4606b","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"00cb6f19-98f0-5279-8ca3-56e9898a856b","slug":"assessment","fullItemName":"Assessment"},{"id":"9a6b352b-2522-507b-baee-3746ed6c5fc1","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"93060cf3-048d-55d8-b979-1ee7c8b333d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"8708236c-483d-548a-bcbb-ece4a63d3ef2","slug":"primary-care-management","fullItemName":"Scenario: Primary care management"}]},{"id":"ff879f6d-4cca-54e7-b137-1bea3673664f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c9958ec-2ef2-5cdd-8066-9039ba251071","slug":"benzoyl-peroxide","fullItemName":"Benzoyl peroxide"},{"id":"6d9ac0d3-8378-55b8-b6dc-17fb87472c20","slug":"topical-retinoids","fullItemName":"Topical retinoids"},{"id":"b3431b25-388f-5ae4-9ae3-fe13143c5d26","slug":"topical-antibiotics","fullItemName":"Topical antibiotics"},{"id":"9ca57669-ad06-5179-885d-5b8063e1323f","slug":"azelaic-acid","fullItemName":"Azelaic acid"},{"id":"8ae4cfcf-ffa5-5d2f-b469-369a52c50963","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"dd897071-f76b-5e49-9c2d-e98f4b853afa","slug":"combined-oral-contraceptives","fullItemName":"Combined oral contraceptives"}]},{"id":"1a455bee-cdcd-5bfe-ac3c-92ebf7dc4f1b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c326d983-7898-5757-a2dd-0324dc5bca9a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7efc9e19-3f3c-5fe4-86af-6645e982294d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5133582b-9a2b-5faf-a3be-a014b639deef","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"10179a08-abca-5ecd-982e-b1147cb710a3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"25e71f93-96a6-5694-a7be-371938647a37","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2adb6ee6-1991-50db-bb70-4a7b3d113064","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9f2f3c9d-3968-50fd-88cb-555214f14d6b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"10279ff1-6a1f-5af9-97b1-73405139911f","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}